AGP Executive Report
Last update: 7 hours agoRegulatory Pressure on Rare-Disease Drugs: EMA advisors say Amgen’s Tavneos (avacopan) should be pulled from sale after CHMP concerns that the ADVOCATE trial breached good clinical practice, with data found incorrect and misleading. Maternal Health Push: India’s Health Ministry will launch the SUMAN Roadmap 2030 to cut maternal and newborn deaths by 2030, using a life-cycle approach and high-risk pregnancy tracking across 130 districts and 13 priority states. AI in Cancer Manufacturing: A new AI-assisted production line for personalized cancer vaccines is rolling out, using rapid tumor DNA analysis to match treatments to patient mutations. Drug Supply Security: Ghana’s Pharmaceutical Society warns that 70% reliance on imported medicines threatens national security and urges investment to raise local manufacturing. Clinical Imaging Setback: FDA denied Lantheus’ application for a new PET imaging agent, citing issues at a third-party manufacturing site. Global Drug Use Record: UN reports 331 million people used drugs in 2024, with cocaine at record levels and a major treatment gap. Healthcare Innovation Ecosystems: New Jersey highlights its life sciences strength in a 2026 report, while Hong Kong launches IHIEA to speed cross-border healthcare innovation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[FDA Approves Risankizumab for Pediatric Psoriasis, Psoriatic Arthritis]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/25217344-913473927-86ae466140c2bffe2138b62607ae471c8ad04ef7-1200x628-100x52.jpeg)
